Document is current
Any future updates will be listed below
-
Authors
Schuelke, Matthew R.
Wongthida, Phonphimon
Thompson, Jill
Kottke, Timothy
Driscoll, Christopher B.
Huff, Amanda L.
Shim, Kevin G.
Coffey, Matt
Pulido, Jose
Evgin, Laura
Vile, Richard G. https://orcid.org/0000-0003-2192-9372
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01 CA175386, R01 CA108961, F30 CA210334)
- License Information
-
More Information
Article History
Received: 22 January 2019
Accepted: 10 July 2019
First Online: 17 July 2019
Ethics approval and consent to participate
: All in vivo studies were performed with the approval of the Mayo Clinic’s Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: Matt Coffey is president and chief executive officer of Oncolytics Biotech, the maker of the reovirus used in this study.
